Loading...
Loading...
PBYI| Name | Value |
|---|---|
| Revenues | 52.4M |
| Cost of Revenue | 12.3M |
| Gross Profit | 40.1M |
| Operating Expense | 33.5M |
| Operating I/L | 6.6M |
| Other Income/Expense | -0.5M |
| Interest Income | 1.0M |
| Pretax | 6.2M |
| Income Tax Expense | 0.3M |
| Net Income/Loss | 5.9M |
Puma Biotechnology, Inc. is a biopharmaceutical company specializing in the development and commercialization of cancer care products. Its drug candidates include PB272 neratinib for early stage HER2-overexpressed/amplified breast cancer, as well as for advanced or metastatic HER2-positive breast cancer and HER2 mutation-positive solid tumors. The company generates revenue through the development and commercialization of these drug candidates, as well as through license and sub-license agreements with various pharmaceutical companies for the distribution and marketing of its products.
